Form Type:  SC 13G
Filing Date:  2/1/2021 
CIK:  0001640455 
Address:  780 MEMORIAL DRIVE 
City, State, Zip:  CAMBRIDGE, Massachusetts 02139 
Telephone:  857-259-3840 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.44 (6.09%)  
Trade Time: 
May 14  
Market Cap: 
Trade JNCE now with 

© 2021  
Description of Business
We are a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Our strategy is to use a biomarker-driven approach from discovery through clinical development. We have developed a suite of integrated technologies that comprise our Translational Science Platform, enabling us to comprehensively interrogate the cellular and molecular composition of tumors. By focusing on specific cell types, both immune and non-immune, within tumors, we can prioritize targets and then identify related biomarkers designed to match the right therapy to the right patient. Our pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors, which represent significant opportunities requiring different biological approaches.
Register and access this filing in:     
  EXHIBIT 99.1